Home / Europe / Hungary / Life Sciences & Healthcare

Life Sciences & Healthcare

We work with and have established long-term relationships with the top 100 life sciences & healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies, the top ten global medical device companies, the largest biotechnology company and start-ups.

Our life sciences & healthcare teams in Central and Eastern Europe advise leading global business groups in the sector on transactions, commercial agreements, compliance, investigations and litigation, very quite often across multiple jurisdictions in the region and beyond. We can help you to navigate the regulatory landscape and to ensure compliance with both local laws and global policies.

With over 480 international specialist lawyers across CMS and the support of the Life Sciences & Healthcare Asia-Pacific Network (LAN), we understand the scientific and commercial aspects, as well as the legal imperatives affecting your life sciences & healthcare business. Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics.
With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB EUCOMED, MedTech Europe and EFPIA , we help shape the legal frameworks impacting the life sciences & healthcare sectors.

We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public procurement, pricing and reimbursement, patents, trademarks and other intellectual property, product liability, anti-trust / competition law, commercial and clinical trial agreements as well as regulatory advice and M&A.

The Life Sciences & Healthcare Team in Hungary has strong sector-specific knowledge and first-hand experience of the market, gained through secondments and working as in-house counsel at Life Sciences & Healthcare companies. The team represents the Hungarian subsidiaries of a number of market-leading companies with a continuously growing number of instructions.

"They handle complex and difficult legal cases with care."

Chambers, 2023

Excellent proactive client approach (and the lawyers are) highly engaged and innovative.

Chambers, 2018
30/07/2019
Highlights of our experience in Lifesciences in Hungary
A subsidiary of a multinational pharmaceutical company on a major investigation initiated by the Hungarian healthcare authority, the rules concerning promotion of medicinal products, medical aids and...

Feed

13/02/2024
Hungary makes changes to labour law, occupational health and safety at...
Hungary has initiated a series of legislative amendments to laws governing labour, occupation health and safety at work, some of which already entered into force on 1 January 2024. Specifically, Hungarian...
30/01/2024
What’s in a name? Updated EMA guideline on naming medicinal products processed...
The updated EMA Guideline on the acceptability of names for human medicinal products processed through the centralised procedure was adopted by CHMP in December 2023 and came into effect on 1 January...
17/01/2024
Hungarian Competition Authority launches study on impact of AI on competition...
On the eve of the European Commission’s calls for contributions on competition in virtual words and generative AI, the Hungarian Competition Authority (HCA) announced that it is launching a market analysis...
08/01/2024
Adapting to the new EU Data Act: implications for medical devices and other...
In recent years, the European Commission developed a European data strategy, which aims to create a single European market in which data can circulate freely. As the European Commission has emphasized...
04/01/2024
CMS Competition Law and Sustainable Development Series Part 4: Sus­tain­ab­il­ity...
The concept of sustainability as it relates to mergersIn Part 1, we discussed that the concept of sustainability varies depending on its context. As addressed in the previous articles of this series (Article...
18/12/2023
Digital health apps and telemedicine in Hungary
Digital Health Apps/Software 1. How is the software within digital health apps classified in your jurisdiction, and what regulation(s) apply? 1.1 Is it considered a “medical device” or a “product”...
Comparable
14/12/2023
CMS Competition Law and Sustainable Development Series Part 4: Sus­tain­ab­il­ity...
In the fourth instalment of this series, we will address in two parts the sustainability considerations that arise within the course of merger procedures and highlight a few important cases and legislation...
08/12/2023
COP28: Global Health Under the Spotlight
Health took centre stage at the first ever ‘Health Day’ at COP28 on 3 December. The program focused the attention of world leaders on the profound public health-related issues stemming from climate...
08/11/2023
CMS Life Sciences Vital Signs, Winter 2023
2023 has seen some significant legal developments impacting the life sciences industry, and as we look ahead to 2024, there are several important developments which we would like to keep our clients informed...
08/11/2023
Cannabis law and legislation in Hungary
Medical use Generally, it is not permitted to grow, import or sell cannabis for medical use in Hungary. The production, manufacturing, export, import, transfer, purchasing, sales, storage, handling...
11/10/2023
Hungary sets cybersecurity fines in decree
A Hungarian government decree (Government Decree 305/2023 (VII. 11.) on the amount of cybersecurity fines, detailed rules of procedure for the imposition and payment of fines) has set down the minimum...
28/09/2023
EP Case Law in Brief: Erroneous Disclosures
“Mistakes in a document do not in themselves constitute prior art such as to prevent the grant of a patent.”So begins section I.C. 4.9 of the Case Law of the Boards of Appeal. This statement, and...